Apidel SA closes third financing round

Apidel SA is developing and formulating new pharmaceutical products based on its ApidSOLTM and ApidCORTM proprietary drug delivery technologies. The technologies enable effective drugs to be formulated into exceptional therapeutic products providing substantial therapeutic benefits including compliance, safety and efficacy, as well as community benefits such as reduced drug wastage and pollution.

The company has raised a significant amount of funds from private investors and was advised by Valley Road Capital during this transaction.The company will use the funds partly to initiate clinical trials for products enabling regional/local delivery of potent drugs to treat ulcerative colitis and atopic dermatitis without risk of systemic drug side-effects, as well as establishing full GMP manufacture of its proprietary molecules.

“It is a privilege to welcome new private investors to share in Apidel’s adventure. This investment recognizes the value of Apidel’s patented technologies, the potential of our products and the quality of our team”, said Alan Cookson, founder and CEO of Apidel SA. “The company can now complete its transition from a pre-clinical to clinical stage company. I am looking forward to working with Apidel’s first-class team and our development partners, as well as the company’s Board of Directors, to ensure the successful market introduction of products using Apidel technology”, he added.

“Under the leadership of Cookson, Apidel has assembled a group of outstanding professionals and strong partners who together will bring to the market technologies conceived and created by innovative research at The University of Geneva. I am proud that this university research is now contributing to the creation of new jobs and inward investment to the Geneva area. These technologies will enable patients to benefit from first-in-class and best-in-class treatments for serious and debilitating chronic illnesses”, said Robert Gurny, founder and CSO of Apidel and co-inventor of ApidSOLTM and ApidCORTM technology at the University of Geneva.

Patrick de Heney, Managing Partner of Valley Road Capital SA said: “We were very pleased to be asked to advise the Apidel team and support them in successfully executing their 3rd private financing round, thus positioning the company well to reap the full benefits of its portfolio of exciting new therapeutic products”.

Apidel’s technologies are protected by a portfolio of granted patents and patent applications. These proprietary technologies enable both local/regional delivery of poorly soluble drugs targeting only affected tissues, as well as extended time controlled-release of a wide range of molecule types for long term treatment from single administration. Apidel develops products for its own pipeline, as well as partnering with selected companies to co-develop products utilizing drug compounds that will benefit from the superior delivery characteristics and patent protection of Apidel formulations.

Apidel has offices in Geneva, and operates its research laboratories within the Geneva life sciences incubator, Eclosion at Plan-les-Ouates.

Pic.Apidel Facebook

(Press release)